Primary hematopoietic cells from DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid phenotype in vitro

Cell Death and Disease

Volumn 3, Issue 7, 2012, Pages

  Moniz, H ^a,b   Gastou, M ^a,b   Leblanc, T ^c   Hurtaud, C ^a,b   Cre Tien A ^a,b   Lecluse Y ^b   Raslova, H ^a,b   Larghero, J ^d,e   Croisille, L ^f   Faubladier, M ^g,h   Bluteau, O ^a,b   Lordier, L ^a,b   Tchernia, G ⁱ   Vainchenker, W ^a,b   Mohandas, N ^j   Da Costa, L ^a,c,e  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f BICÊTRE HOSPITAL   (France)

^g CNRS   (France)

^h Université Paul Sabatier   (France)

ⁱ Centre de Pistage de la Drépanocytose   (France)

^j NEW YORK BLOOD CENTER   (United States)

more..

Author keywords

apoptosis; cell cycle DBA group of Soci ; d'H matologie et d'Immunologie p diatrique (SHIP); DBA; p53; RPL11; RPS19; t

Indexed keywords

CASPASE 3; PROTEIN BAX; PROTEIN BCL XL; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; RIBOSOME PROTEIN; SHORT HAIRPIN RNA; CD34 ANTIGEN; RIBOSOMAL PROTEIN L11; RIBOSOMAL PROTEIN S19; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BIOGENESIS; BLACKFAN DIAMOND ANEMIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; IN VITRO STUDY; MALE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; ERYTHROID CELL; GENETICS; INFANT; METABOLISM; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; RNA INTERFERENCE;

ANEMIA, DIAMOND-BLACKFAN; ANTIGENS, CD34; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHILD, PRESCHOOL; ERYTHROID CELLS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; PHENOTYPE; RIBOSOMAL PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864869261     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.88     Document Type: Article

References (34)

1. Tissing WJ, Meijerink JP, den Boer ML, Pieters R. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 2003; 17: 17-25.
2. Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004; 11(Suppl 1): S45-S55. (Pubitemid 39136798)
3. Bachmann PS, Gorman R, Papa RA, Bardell JE, Ford J, Kees UR et al. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res 2007; 67: 4482-4490.
4. Planey SL, Litwack G. Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun 2000; 279: 307-312.
5. Distelhorst C.W. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ 2002; 9: 6-19.
6. Frankfurt O, Rosen S.T. Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol 2004; 16: 553-563.
7. Ploner C, Rainer J, Lobenwein S, Geley S, Kofler R. Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells. Apoptosis 2009; 14: 821-828.
8. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green D.R. The BCL-2 family reunion. Mol Cell 2010; 37: 299-310.
9. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
10. Rambal AA, Panaguiton ZL, Kramer L, Grant S, Harada H. MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. Leukemia 2009; 23: 1744-1754.
11. Zhao YN, Guo X, Ma ZG, Gu L, Ge J, Li Q. Pro-apoptotic protein BIM in apoptosis of glucocorticoid-sensitive and -resistant acute lymphoblastic leukemia CEM cells. Med Oncol 2011; 28: 1609-1617.
12. Jiang N, Koh GS, Lim JY, Kham SK, Ariffin H, Chew FT et al. BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. Exp Hematol 2011; 39: 321-329.
13. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer P.J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000; 10: 1201-1204.
14. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003; 162: 613-622.
15. Essafi A, Fernandez de Mattos S, Hassen YA, Soeiro I, Mufti GJ, Thomas NS et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr- Abl-expressing cells. Oncogene 2005; 24: 2317-2329.
16. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 2001; 29: 629-643.
17. Biswas SC, Shi Y, Sproul A, Greene L.A. Pro-apoptotic Bim induction in response to nerve growth factor deprivation requires simultaneous activation of three different death signaling pathways. J Biol Chem 2007; 282: 29368-29374.
18. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 2005; 102: 16090-16095.
19. Yano T, Ito K, Fukamachi H, Chi XZ, Wee HJ, Inoue K et al. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor betainduced apoptosis. Mol Cell Biol 2006; 26: 4474-4488.
20. Wildey GM, Howe P.H. Runx1 is a co-activator with FOXO3 to mediate transforming growth factor beta (TGFbeta)-induced Bim transcription in hepatic cells. J Biol Chem 2009; 284: 20227-20239.
21. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010; 116: 3013-3022.
22. Matsui H, Asou H, Inaba T. Cytokines direct the regulation of Bim mRNA stability by heatshock cognate protein 70. Mol Cell 2007; 25: 99-112.
23. Ley R, Ewings KE, Hadfield K, Cook S.J. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 2005; 12: 1008-1014.
24. Lu J, Quearry B, Harada H. p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells. FEBS Lett 2006; 580: 3539-3544.
25. Zhou F, Thompson E.B. Role of c-jun induction in the glucocorticoid- evoked apoptotic pathway in human leukemic lymphoblasts. Mol Endocrinol 1996; 10: 306-316.
26. Brown PH, Chen TK, Birrer M.J. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 1994; 9: 791-799.
27. Freemerman AJ, Turner AJ, Birrer MJ, Szabo E, Valerie K, Grant S. Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C. Mol Pharmacol 1996; 49: 788-795.
28. Cai B, Xia Z. p38 MAP kinase mediates arsenite-induced apoptosis through FOXO3a activation and induction of Bim transcription. Apoptosis 2008; 13: 803-810.
29. Molitoris JK, McColl KS, Distelhorst C.W. Glucocorticoid-mediated repression of the oncogenic microRNA cluster miR-17B92 contributes to the induction of Bim and initiation of apoptosis. Mol Endocrinol 2011; 25: 409-420.
30. Blyth K, Vaillant F, Jenkins A, McDonald L, Pringle MA, Huser C et al. Runx2 in normal tissues and cancer cells: A developing story. Blood Cells Mol Dis 2010; 45: 117-123.
31. Eliseev RA, Dong YF, Sampson E, Zuscik MJ, Schwarz EM, O'Keefe RJ et al. Runx2- mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis. Oncogene 2008; 27: 3605-3614.
32. Goloudina AR, Tanoue K, Hammann A, Fourmaux E, Le Guezennec X, Bulavin DV et al. Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proc Natl Acad Sci USA 2012; 109: E68-E75.
33. Ausserlechner MJ, Obexer P, Bock G, Geley S, Kofler R. Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells. Cell Death Differ 2004; 11: 165-174.
34. Zhou F, Medh RD, Zhang W, Ansari NH, Thompson E.B. The delayed induction of c-jun in apoptotic human leukemic lymphoblasts is primarily transcriptional. J Steroid Biochem Mol Biol 2000; 75: 91-99.